BioNexus Gene Lab Corp. (NASDAQ:BGLC) Short Interest Update

BioNexus Gene Lab Corp. (NASDAQ:BGLC) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 3,503 shares, a decline of 76.1% from the June 30th total of 14,642 shares. Based on an average daily volume of 5,583 shares, the short-interest ratio is presently 0.6 days. Approximately 0.1% of the shares of the company are sold short.

BioNexus Gene Lab Stock Performance

BGLC stock traded down $0.03 during midday trading on Friday, reaching $1.51. The company had a trading volume of 4,816 shares, compared to its average volume of 5,025. The firm has a market capitalization of $3.65 million, a PE ratio of -1.02 and a beta of 4.08. The stock has a 50 day moving average price of $2.06 and a 200 day moving average price of $2.36. BioNexus Gene Lab has a fifty-two week low of $1.07 and a fifty-two week high of $8.98. The company has a quick ratio of 5.69, a current ratio of 6.53 and a debt-to-equity ratio of 0.01.

BioNexus Gene Lab (NASDAQ:BGLC) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter. BioNexus Gene Lab had a negative return on equity of 37.43% and a negative net margin of 54.70%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BioNexus Gene Lab stock. DRW Securities LLC boosted its stake in BioNexus Gene Lab Corp. (NASDAQ:BGLC) by 226.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,830 shares of the company’s stock after buying an additional 33,179 shares during the period. DRW Securities LLC owned 2.02% of BioNexus Gene Lab worth $189,000 as of its most recent SEC filing. 18.85% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

BioNexus Gene Lab Company Profile

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers.